Company intelligence / Profile preview
Leap Therapeutics, Inc.
Cambridge, Massachusetts, United Statesleaptx.com ↗
- Ownership
- Public · LPTX
- Employees
- ~100
- Development stage
- Other
01
Overview
Leap's lead candidate sirexatamab (DKN-01) has shown promising results in Phase 2 trials, including a 32% higher overall response rate and 3.5 month longer progression-free survival in colorectal cancer patients with high DKK1 levels. The company has completed enrollment in the expanded Part B of the DeFianCe study for colorectal cancer and is continuing patient follow-up in the DisTinGuish study for gastroesophageal cancer.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Leap Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leap Therapeutics, Inc..